{
    "clinical_study": {
        "@rank": "65579", 
        "arm_group": [
            {
                "arm_group_label": "Totalis\u2122 Direct Decompression Procedure", 
                "arm_group_type": "Active Comparator", 
                "description": "Totalis"
            }, 
            {
                "arm_group_label": "Sham Surgical Procedure", 
                "arm_group_type": "Sham Comparator", 
                "description": "Sham"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine safety and effectiveness, as measured by changes\n      in pain, disability, patient satisfaction, and claudicatory symptoms, at 6 months following\n      treatment with the Totalis\u2122 Direct Decompression System or Sham Surgery in patients with\n      lumbar spinal stenosis"
        }, 
        "brief_title": "The STEPS - Totalis\u2122 Trial", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Lumbar Spinal Stenosis", 
        "condition_browse": {
            "mesh_term": [
                "Constriction, Pathologic", 
                "Spinal Stenosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects suffering from symptoms of neurogenic intermittent claudication secondary to a\n      radiographically-confirmed diagnosis of central canal stenosis, with or without mild or\n      moderate lateral recess stenosis, at one or two levels from L1 to L5 who meet all\n      inclusion/exclusion criteria, including \u22656 months of non-operative management.\n\n      Patients included in the clinical investigation will return for follow-up visits at 1 week\n      for safety evaluation, and at 6 weeks, 3 months, 6 months, 12 months, 18 months and 24\n      months post-treatment to collect data for evaluation of safety and effectiveness."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects 55 to 85 years of age\n\n          -  Neurogenic intermittent claudication (NIC) symptoms defined generally as leg/buttock/\n             groin pain and/or paresthesias that are exacerbated with standing and walking and\n             relieved by flexion\n\n          -  VAS leg symptom severity >50 (in either leg) during episodes of neurogenic\n             claudication\n\n          -  Subjects who are able to walk a minimum of 50 feet without experiencing NIC symptoms\n\n          -  Diagnosis of central canal spinal stenosis, with or without mild to moderate lateral\n             recess stenosis, at one or two levels from L1-L5 with radiologic evidence\n\n          -  Subjects with persistent lumbar spinal stenosis symptoms that, during the course of\n             the last year, have been unresponsive to a minimum of 6 months of conservative\n             therapy\n\n        Exclusion Criteria:\n\n          -  Significant back, buttock or leg pain from causes other than lumbar central canal\n             stenosis\n\n          -  Axial back pain only\n\n          -  Severe foraminal stenosis at index level(s) and/or symptomatic foraminal stenosis at\n             any lumbar level\n\n          -  Severe lateral recess stenosis\n\n          -  Lumbar spinal stenosis at more than two levels determined pre-operatively to require\n             surgical intervention\n\n          -  Prior decompressive surgery at index level (s) or fusion at any lumbar level\n\n          -  Epidural steroid or nerve block steroid injection at index level(s) within 6 weeks of\n             baseline assessments\n\n          -  Spondylolisthesis (anterolisthesis or retrolisthesis) greater than grade 1\n\n          -  Spondylolysis (pars fracture)\n\n          -  Significant degenerative lumbar scoliosis at index level(s)\n\n          -  Morbid obesity\n\n          -  Significant peripheral vascular disease\n\n          -  Active significant co-morbidity\n\n          -  Undergoing immunosuppressive therapy or long-term steroid use\n\n          -  Current spinal cord stimulator or implanted pain pump\n\n          -  Life expectancy less than 2 years\n\n          -  Evidence of substance abuse within the year\n\n          -  Involvement or potential involvement in litigation related to the spine or worker's\n             compensation related to a back and/or leg issue"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079038", 
            "org_study_id": "14-TDDS-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Totalis\u2122 Direct Decompression Procedure", 
                "intervention_name": "Totalis", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Sham Surgical Procedure", 
                "intervention_name": "Sham", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Shawn Potts", 
                    "phone": "541-686-3791"
                }, 
                "facility": {
                    "address": {
                        "city": "Eugene", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97401"
                    }, 
                    "name": "NeuroSpine Institute"
                }, 
                "investigator": [
                    {
                        "last_name": "Gregory Moore, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Gregory Philips, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kay Bovee", 
                    "phone": "804-330-0303"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23235"
                    }, 
                    "name": "Virginia iSpine Physicians"
                }, 
                "investigator": [
                    {
                        "last_name": "Michael J. DePalma, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "James Sanderlin, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multi-center, Randomized Controlled Double-Blind Trial Evaluating the VertiFlex\u00ae Totalis\u2122 Direct Decompression System Versus a Sham Surgical Procedure in Patients With Lumbar Spinal Stenosis", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Centers for Medicare and Medicaid Services", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of patients who achieve the minimum clinically important difference (MCID) in any two of three domains of the Zurich Claudication Questionnaire (ZCQ) at 6 months and no interventions through 6 months", 
            "safety_issue": "No", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079038"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Visual Analogue Scale (VAS): Compared to baseline, an improvement (in leg and/or back pain) of 20 mm (on a 100mm scale)  is considered clinically significant", 
            "measure": "Visual Analogue Scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "6 Months"
        }, 
        "source": "VertiFlex, Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "VertiFlex, Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}